Philips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025

Rhea-AI Summary

Philips (NYSE:PHG) unveiled innovative CT and MR solutions for radiation therapy at ASTRO 2025. The company introduced two new CT platforms - Rembra RT and Areta RT - featuring ultra-fast image reconstruction speeds of up to 106 images per second and an extended 85cm field of view.

Additionally, Philips debuted the helium-free BlueSeal RT 1.5T 70cm MR system in North America, powered by AI-based SmartSpeed Precise acceleration software. The system enables MR-only simulation protocols in as little as 10 minutes and features a lightweight, vent-pipe-free design for flexible installation options.

Both innovations aim to enhance radiation therapy planning with improved accuracy, efficiency, and sustainability while reducing operational costs and improving patient experience.

Positive

• New CT platforms offer ultra-fast image reconstruction speeds of 106 images/second
• Tube for Life Guarantee and potential 20-year service life reduce long-term costs
• Helium-free MR system design reduces operational costs and energy consumption
• 91% of care teams report improved workflow efficiency with new touchscreen controls

Negative

• Rembra RT and Areta RT platforms are pending 510(k) clearance, not yet available for sale in US

News Market Reaction

+0.98%

1 alert

+0.98% News Effect

On the day this news was published, PHG gained 0.98%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

September 26, 2025

• New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value
• Philips debuts helium-free [2] BlueSeal RT 1.5T 70cm MR system with AI-powered SmartSpeed Precise, expanding its leadership in sustainable MR for radiation oncology

Amsterdam, the Netherlands – At the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will introduce groundbreaking additions in radiation oncology: the Philips Rembra RT and Philips Areta RT CT platforms, and the latest helium-free [2] BlueSeal RT 1.5T MR system. Designed to help radiation oncology teams deliver highly accurate, efficient, and patient-centered care, innovative technologies like the new NanoPanel Precise XD detector, built for AI and the AI-based Smartspeed Precise, represent a significant step forward in tackling the growing complexities of radiation therapy planning.


Setting new standards in CT simulation with speed, accuracy, and long-term value
CT imaging is the foundation of precision in radiation therapy planning, delivering accuracy to guide treatment. But as oncology teams face mounting demands for precision, efficiency, and consistency amid staffing and resource pressures, a new era of CT simulation is rising to meet the challenge.

Philips’ new Rembra RT and Areta RT systems are designed to make cancer treatment planning faster and more accurate.  These advanced scanners produce clearer, more consistent images so doctors can see tumors in greater detail and plan treatments with confidence. They also save valuable time with ultra-fast image reconstruction speeds up to 106 images per second, and easy-to-use touchscreen gantry controls that help 91% of care teams work more efficiently [3]. A wide 85 cm extended field of view and next-generation 4DCT imaging capabilities can capture a full respiratory cycle in one scan up to 500 scan seconds with breath rates of 4-40 breaths per minute.

Beyond imaging, the systems support remote collaboration for planning and training, helping care teams stay connected and efficient without adding extra staff. And with Philips’ industry-first Tube for Life Guarantee and a design for which 20 years of service could be provided (provided commercial upgrades and maintenance), hospitals gain reliable, long-term value while keeping costs lower. Patients also benefit directly, with a high-performance table that allows flexible positioning, faster workflows that shorten waiting times, and shared-use radiology capabilities on Rembra RT to maximize department efficiency.

“Philips invented CT Simulation and introduced the industry’s first Big Bore RT system,” said Dan Xu, Business Leader of CT at Philips. “With Rembra RT and Areta RT, we’re once again setting new standards in radiation therapy, empowering care teams with the precision, dependability, and speed they need to deliver the best outcomes for patients.”

Philips is also currently working with MVision AI to explore opportunities to include MVision AI’s Contour+ AI-powered auto-segmentation software with Philips CT simulators, including the new Rembra RT and Areta RT systems.  Contour+ delivers fast and precise automatic delineation of organs at risk and lymph node areas.

Philips expands MR leadership with helium-free BlueSeal RT [4]
Alongside its newest CT innovations, Philips is introducing BlueSeal MR RT in North America [5], the company’s latest helium-free [2] 1.5T 70cm MR system designed for radiation oncology. Powered by AI-based SmartSpeed Precise acceleration software, BlueSeal RT enables enhanced simulation confidence.

MR plays an increasingly vital role in radiation therapy, enabling clinicians to visualize tumors and surrounding healthy tissue with far greater detail, which is essential for planning precise treatments. By combining sustainability with advanced imaging, BlueSeal RT transforms therapy planning with enhanced simulation confidence, reducing registration errors to help protect healthy organs. In addition, MR-only imaging with MRCAT simplifies workflows. With full MR-only simulation protocols in as little as 10 minutes, patients also benefit, experiencing shorter scans that improve comfort and overall experience, especially for those wearing a mask.

With approximately 2,000 helium-free [2] MR scanners installed worldwide, Philips is driving the shift to sustainable MR. BlueSeal RT extends this leadership into radiotherapy by addressing a key challenge for oncology departments: installing MR systems in complex clinical environments such as Radiation Oncology departments. Its light-weight, vent-pipe-free design opens new siting possibilities - whether in basements, bunkers, or higher floors - while also lowering cost and energy use through helium-free [2] operation and PowerSave+ efficiency.

“BlueSeal RT is leading the way in MR for radiotherapy,” said Ioannis Panagiotelis, PhD, Business Leader MR at Philips. “By combining helium-free [2] sustainability with AI-powered acceleration, we’re enabling radiation oncology teams to plan and simulate with greater speed, accuracy, and confidence—while enhancing the patient experience.”

“Radiation oncology teams need transformative innovation to meet today’s accuracy, workflow, and cost challenges,” said Christopher M. Freese, MD, The Christ Hospital. “With Rembra RT, Areta RT, and BlueSeal RT, Philips is setting new standards for precision and efficiency in radiation therapy across CT and MR.” 

For more information, visit Philips at ASTRO 2025.

[1] 510(k) pending. Not available for sale in the US.
[2] 7 liters of helium are permanently enclosed in the cryogenic circuit.
[3] Based on a third-party survey of 145 users across eight countries. Quantitative Report 2020 Incisive CT. The MarketTech Group. November, 2020. Actual results in other cases may vary.
[4] BlueSeal RT is a configuration of BlueSeal XE/SE.
[5] BlueSeal RT is an add-on to the existing Ingenia 1.5T and 3.0T MR systems that makes the system suitable for MR imaging for radiation therapy planning purposes. BlueSeal RT consists of RTGo SW and MR CouchTop accessory. RTgo is a software that provides MR-RT functionality including MRCAT (MRCAT Prostate, MRCAT Pelvis, MRCAT Brain, MRCAT Head &Neck)

For further information, please contact:

Kathy O’Reilly
Philips Global External Relations
Tel.: +1 978-221-8919
E-mail: kathy.oreilly@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips news RembraRT CT Platform - 01
• Philips news RembraRT CT Platform - 02
• Philips BlueSeal MR RT in use - 01
• Philips BlueSeal MR RT in use - 02

FAQ

What new radiation therapy technologies did Philips (PHG) announce at ASTRO 2025?

Philips announced two new CT platforms (Rembra RT and Areta RT) and the helium-free BlueSeal RT 1.5T 70cm MR system, designed to enhance radiation therapy planning with improved accuracy and efficiency.

What are the key features of Philips' new Rembra RT and Areta RT CT platforms?

The platforms feature ultra-fast image reconstruction (106 images/second), 85cm extended field of view, next-gen 4DCT imaging, and touchscreen controls that improve efficiency for 91% of care teams.

How does the new Philips BlueSeal RT MR system improve radiation therapy planning?

BlueSeal RT enables MR-only simulation protocols in 10 minutes, features AI-based SmartSpeed Precise software for enhanced simulation confidence, and operates helium-free for reduced costs and environmental impact.

What cost benefits do the new Philips radiation therapy systems offer?

The systems offer significant cost benefits through the Tube for Life Guarantee, potential 20-year service life, and helium-free operation in the BlueSeal RT MR system, reducing long-term operational expenses.

When will Philips' new Rembra RT and Areta RT platforms be available in the US?

The platforms are currently pending 510(k) clearance and are not yet available for sale in the United States.